Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 15, 2008

View Archived Issues

Partial alphavbeta6 inhibition prevents lung fibrosis without increasing inflammation

Potent analgesic activity of ABT-102 in preclinical studies

Intranasal versus i.v. orexin-A in memory enhancement of sleep-deprived monkeys

LFB and GTC enter collaboration for coagulation factor IX program for type B hemophilia

Cadence reports topline results from the 301 and 302 phase III clinical trials of Acetavance

Starpharma expands phase I trial of VivaGel and completes enrollment in herpes study

Hemispherx submits responses to FDA questions on NDA for Ampligen for CFS

Nucleonics initiates phase I human safety study of NUC-B1000 for chronic HBV infection

The immunosuppressant FTY-720 shows promise in hematological cancer

Aviation Upgrade Technologies changes its name to OncoVista Innovative Therapies

Adventrx reports ANX-530 safety data and plans NDA submission

Diamyd submits IND for phase I novel chronic pain therapy trial

FDA extends review of Genasense NDA appeal

Pharmion submits E.U. MAA for Vidaza in patients with MDS

Protherics and Advancell enroll first patient in B-cell lymphocytic leukemia study

Novel psychopharmacologic drugs described

Ube and Santen patent claims novel agents for glaucoma

JAK3/CDK4 inhibitors emerge from Novartis R&D

Tysabri approved in U.S. for moderate to severe Crohn's disease

Novo Nordisk discontinues development of AERx inhaled insulin

Wellcome Trust awards GBP 3.5 million to Novacta to target Clostridium difficile

Alder completes USD 40M series C financing and advances development of ALD-518

CollaGenex initiates phase II clinical trial of vitamin D analogue becocalcidiol for psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...